Effect of SGLT2 Inhibitors on Anemic CKD Patients

N/ANot Yet RecruitingNCT07334145

Sohag University60 enrolled

Overview

anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its complications. the SGLT2 inhibitors have emerging evidence from major clinical trials in improving anemia in patients with CKD

Study Type

OBSERVATIONAL

Enrollment

Conditions

Anemia in CKD Patients

Interventions

SGLT2 inhibitorDRUG

prescription of SGLT2 inhibitors like dapagliflozin or empagliflozin to anemic CKD patients stage 1\_4

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * age more than 18 years * CKD stage 1\_4 * baseline hemoglobin 8.5 to 12.9 g/dl * stable anemia regimen for more than 8 weeks Exclusion Criteria: * dialysis recent blood transfusion or ESA dose change within 8 weeks active malignancy or infection pregnancy or lactation history of recurrent DKA or sever volume depletion

Locations (1)

Sohag University Hospital

Sohag, Sohag University, Egypt

Outcomes

Primary Outcomes

hemoglobin level

use the hemoglobin level to assist the effect of SGLT2 inhibitors On anemia correction

Time frame: 12 weeks

change in hemoglobin level

anemia correction

Time frame: 12 weeks

Central Contacts

Romany Naguib Mikhaeil, master

CONTACT

01274426883 romanynaguib977@gmail.com

Ahmed Nagah NourEldin, associate professor

CONTACT

01127022717 ahmednagah3000@yahoo.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.